Categories: Health

Precise Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

GREENSBORO, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) — Precise Bio, Inc. (“Precise Bio” or the “Company”), a clinical-stage regenerative medicine company pioneering bio-printed tissues and organs with an initial focus on ophthalmology, today announced that Aryeh Batt, Co-Founder and Chief Executive Officer will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 25-26, 2026. The executive team will also be available for one-on-one meetings with investors throughout the conference.

Format: Company Presentation, Live Webcast

Date/Time: Thursday, February 26, 2026, at 8:00 am ET

About Precise Bio

Precise Bio is a clinical-stage regenerative medicine company pioneering tissue engineering using its proprietary 3D-bio-fabrication platform, which integrates cell biology and biomaterials to produce clinical-grade human tissues under GMP conditions. Its lead program, PB-001, is the world’s first bio-printed corneal implant to enter human clinical trials, with additional ophthalmology and advanced tissue programs in development. For more information, visit www.precise-bio.com.

Contact

Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com

GlobeNews Wire

Recent Posts

NYSE Content Update: ICE Chat Connects with Crypto Platform Kraken to Up Access

NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, Feb. 18, 2026…

23 minutes ago

Milo Crosses $100 Million Crypto Mortgage Milestone, Closes Record $12 Million Transaction

Milo continues to lead crypto lending, supporting digital asset holders with flexible financing options for…

23 minutes ago

Shriram Finance Earns Great Place To Work Certification for the Third Consecutive Year

MUMBAI, India, Feb. 18, 2026 /PRNewswire/ -- Shriram Finance Limited (SFL), the flagship company of…

23 minutes ago

ACTG Announces Publication of LATITUDE Findings in the New England Journal of Medicine

Study Confirms Long-Acting Treatment is Effective among People Living with HIV Who Experience Challenges Taking…

1 hour ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq:…

1 hour ago

Lifespan Vision Ventures Co-Leads Sift Biosciences’ $3.7M Pre-Seed Financing

NORWALK, Conn., Feb. 18, 2026 /PRNewswire/ -- Lifespan Vision Ventures, an investment firm focused on…

5 hours ago